Triple Negative Breast Cancer Pipeline Assessment 2023 | Clinical Trials Analysis, Latest FDA Approvals, Treatment, Therapies, Competitive Landscape, and Companies by DelveInsight

May 02 17:11 2023
Triple Negative Breast Cancer Pipeline Assessment 2023 | Clinical Trials Analysis, Latest FDA Approvals, Treatment, Therapies, Competitive Landscape, and Companies by DelveInsight
Triple Negative Breast Cancer Pipeline
Upcoming therapies, such as TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics), and others, have the potential to create a significant positive shift in the TNBC market size and the treatment scenario.

(Albany, USA)  “Triple Negative Breast Cancer Pipeline Insight, 2023” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Triple Negative Breast Cancer Therapeutics Market.

As per DelveInsight, the Triple Negative Breast Cancer therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing incident population of TNBC patients, the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the launch of new therapies in the market.


To know more about the TNBC pipeline Report offerings and trends, request for a free sample report @ Triple Negative Breast Cancer Drug Pipeline Analysis


The Leading Players in the Triple Negative Breast Cancer Therapeutics Market Include:

  • Astellas
  • AstraZeneca
  • Clovis Oncology
  • CytoDyn
  • Gilead Science
  • HiberCell
  • Hoffmann-La Roche
  • Immunomedics
  • Imprime PGG
  • Infinity Pharmaceuticals
  • Merck
  • Roche
  • Tesaro
  • And Many Others


Triple Negative Breast Cancer Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Triple Negative Breast Cancer Market.
  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer treatment.
  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Triple Negative Breast Cancer market.


Learn More about the Clinical and Commercial Development Activities in the Triple Negative Breast Cancer Therapeutics Domain:


The Report Covers the Emerging TNBC Pipeline Products Under Different Phases of Clinical Development Like –

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Request for Sample PDF to Understand More About the TNBC Treatment Outlook and Future Perspectives:


Triple Negative Breast Cancer Therapeutics Analysis

Currently, the treatment paradigm for TNBC includes a few treatment options, such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery, and radiation. The Triple Negative Breast Cancer market holds few US FDA-approved drugs, such as KEYTRUDA (pembrolizumab) by Merck Sharpe and Dohme, LYNPARZA (olaparib) by AstraZeneca, TRODELVY (sacituzumab govitecan) by Gilead Sciences, etc. However, various off-label drugs are used for treating TNBC, which include Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel, etc. To further improve the treatment scenario, several major pharma and biotech giants are actively working in the Triple Negative Breast Cancer Therapeutics market.


Triple Negative Breast Cancer Emerging and Marketed Therapies Covered in the Report Include:

  • Atezolizumab: Roche
  • Capitasertib: AstraZeneca
  • Cobimetinib: Roche
  • Enzalutamide: Pfizer/Astellas
  • HiberCell: Imprime PGG
  • Ipatasertib: Roche
  • IPI-549 (Eganelisib): Infinity Pharmaceuticals
  • KEYTRUDA (pembrolizumab): Merck & Co
  • Niraparib: Tesaro
  • Pembrolizumab: Merck
  • Rucaparib: Clovis Oncology
  • Sacituzumab Govitecan: Immunomedics
  • TRODELVY (sacituzumab govitecan-hziy): Gilead Sciences
  • HiberCell: Imprime PGG
  • MDNA11: Medicenna Therapeutics
  • Leronlimab (PRO 140): CytoDyn
  • And Many More


Get an in-depth Assessment of the Emerging Triple Negative Breast Cancer Therapies and Key Companies:


Table of Content

1. Report Introduction

2. Executive Summary

3. Triple Negative Breast Cancer Current Treatment Patterns

4. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Triple Negative Breast Cancer Late-Stage Products (Phase-III)

7. Triple Negative Breast Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Triple Negative Breast Cancer Discontinued Products

13. Triple Negative Breast Cancer Product Profiles

14. Triple Negative Breast Cancer Key Companies

15. Triple Negative Breast Cancer Key Products

16. Dormant and Discontinued Products

17. Triple Negative Breast Cancer Unmet Needs

18. Triple Negative Breast Cancer Future Perspectives

19. Triple Negative Breast Cancer Analyst Review

20. Appendix

21. Report Methodology


Get Detailed Insights About the Reports Offerings:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States